tyvaso dpi
(treprostinil)United Therapeutics Corporation
Usage: Tyvaso DPI is indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability in patients, particularly those with NYHA Functional Class III symptoms. It is also indicated for pulmonary hypertension associated with interstitial lung disease (PH-ILD) to enhance exercise capacity.